Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma - PubMed
6 hours ago
- #DLBCL
- #targeted therapy
- #immunotherapy
- R-CHOP has been the standard first-line treatment for DLBCL, but pola-R-CHP is emerging as a new option.
- Novel therapies targeting signaling pathways, cellular antigens, and epigenetic regulators are in development for high-risk DLBCL.
- Treatment strategies are being tailored to cell of origin or molecular subtypes using subtype-specific targeted agents.
- Agents effective in relapsed/refractory DLBCL, such as tafasitamab and golcadomide, are under investigation for newly diagnosed patients.
- Immunotherapies like anti-CD19 CAR-T therapy and CD20×CD3 bispecific antibodies are being evaluated as early-line therapies after success in relapsed/refractory disease.
- Bispecific antibodies enable flexible treatment strategies, including combinations with cytotoxic or chemotherapy-free approaches.